10-K: Alexandria Real Estate Equities Reports 2025 Results

Alexandria Real Estate Equities, Inc. reported a net loss of $1.44 billion for 2025, a significant decline from 2024, driven by substantial real estate impairments and a dividend reduction, amidst challenging life science market conditions.

Summary

• Alexandria Real Estate Equities, Inc. (ARE) reported a net loss attributable to common stockholders of $1.438 billion, or $8.44 per share, for the year ended December 31, 2025, compared to a net income of $309.6 million, or $1.80 per share, in 2024.
• Funds from operations (FFO) diluted, as adjusted, decreased to $9.01 per share in 2025 from $9.47 per share in 2024.
• Total revenues for 2025 were $3.03 billion, a 2.9% decrease from $3.12 billion in 2024, primarily due to real estate dispositions.
• Net operating income (cash basis) increased by 0.1% to $1.98 billion in 2025, but Same Property Net Operating Income (NOI) decreased by 3.5% (GAAP basis) and increased by 0.9% (cash basis).
• Operating occupancy for North America properties declined to 90.9% as of December 31, 2025, from 94.6% in 2024, and is projected to further decline to 88.5% by December 31, 2026.
• Rental rates on renewed and re-leased space increased by 7.0% (GAAP) and 3.5% (cash basis) in 2025.
• The company executed 205 leases for 4.2 million RSF in 2025, with 82% of activity from existing tenants.
• General and administrative (G&A) expenses decreased by 30.5% to $117.0 million in 2025, representing 5.6% of NOI, the lowest in a decade.
• A quarterly cash dividend of $0.72 per common share was declared for Q4 2025, a 45% reduction from the $1.32 declared for Q3 2025, to preserve liquidity.
• The company completed $1.81 billion in dispositions and sales of partial interests in 2025, exceeding its guidance midpoint, and targets $2.90 billion for 2026.
• Real estate impairment charges aggregated $2.20 billion in 2025, significantly higher than $223.1 million in 2024, primarily due to reevaluation of projects and assets held for sale.
• Future construction funding requirements were reduced by over $300 million, with 3.5 million RSF of Class A/A+ properties currently under construction.
• The company expects to self-fund a large portion of its 2026 capital requirements through operating cash flows ($525 million after dividends) and dispositions ($2.90 billion).
• Net debt and preferred stock to Adjusted EBITDA was 5.7x and fixed-charge coverage ratio was 3.7x for Q4 2025 annualized.
• Weighted-average remaining term of debt is 12.1 years, with 97.2% fixed-rate debt.
• A lawsuit was filed against New York City Health + Hospitals Corporation (H+H) and New York City Economic Development Corporation (EDC) regarding a land parcel option for a future life science building, with $178.1 million in pre-construction costs invested.
• Joel S. Marcus's 2025 Long-Term Incentive Grant (LTI Grant) was modified to be 100% performance-based vesting, with a maximum value of $5.4 million.
• John Hart Cole was promoted to Co-President and Co-Regional Market Director – Seattle, with an annual salary increase to $775,000, effective January 1, 2026.

Sentiment

Score: 3

Explanation: The company reported a significant net loss, a dividend cut, substantial asset impairments, and projected declines in occupancy and rental rates for 2026. While management highlights mitigating factors and strategic strengths, the overall financial performance and market outlook presented are strongly negative, indicating a challenging period ahead.

Positives

• General and administrative expenses decreased by 30.5% to $117.0 million in 2025, reaching 5.6% of net operating income, the lowest in over a decade and approximately half the average of other S&P 500 REITs.
• Successful execution of capital recycling strategy, completing $1.81 billion in dispositions and sales of partial interests in 2025, exceeding guidance.
• Strong tenant collections, with 99.9% of tenant rents and receivables collected for Q4 2025.
• High percentage of leases (97%) containing effective annual rent escalations approximating 3%, providing stable cash flows.
• Majority of leases (92%) are triple net, requiring tenants to pay most operating expenses and certain capital expenditures, mitigating inflation impact on net operating income.
• Weighted-average remaining lease term of 7.5 years for all tenants and 9.7 years for top 20 tenants, indicating long-term revenue stability.
• Significant liquidity of $5.30 billion as of December 31, 2025, providing financial flexibility.
• Strong credit ratings of BBB+ (S&P Global Ratings) and Baa1 (Moody's Ratings), ranking in the top 15% among publicly traded U.S. REITs.
• Well-laddered debt maturity schedule, with only 11% of total debt maturing through 2028, and a weighted-average remaining term of 12.1 years, the longest among S&P 500 REITs.
• 77% of the total development and redevelopment pipeline RSF is within Megacampus ecosystems, which are considered the most competitive segment of the life science real estate market.
• 82% of 2025 leasing activity was generated from the existing tenant base, reflecting strong tenant relationships.
• The company's operational excellence team, composed of highly experienced facilities specialists, ensures a secure and efficient environment for scientific research.
• Improvement in the office market, particularly from the technology sector (AI), is absorbing some supply previously anticipated for life science use, potentially alleviating oversupply in the life science sector.
• Proactive reduction in capital spending and funding needs, with average annual construction spending expected to decline by 37% for 2024-2026 compared to 2021-2023 average.

Negatives

• Net loss attributable to common stockholders of $1.438 billion in 2025, a significant decline from net income of $309.6 million in 2024.
• Funds from operations (FFO) diluted, as adjusted, decreased to $9.01 per share in 2025 from $9.47 per share in 2024.
• Total revenues decreased by 2.9% to $3.03 billion in 2025.
• Same Property Net Operating Income (NOI) decreased by 3.5% (GAAP basis) for the year ended December 31, 2025.
• Operating occupancy in North America declined to 90.9% as of December 31, 2025, from 94.6% in 2024, and is projected to further decline to 88.5% by December 31, 2026.
• Rental rate changes on renewed and re-leased space (cash basis) were 3.5% in 2025, a significant drop from 7.2% in 2024, and are projected to decline further to -12.0% to -4.0% in 2026.
• Significant real estate impairment charges of $2.20 billion in 2025, compared to $223.1 million in 2024, reflecting lower property valuations and increased capitalization rates.
• Dividend reduction of 45% for Q4 2025 to $0.72 per share from $1.32 per share in Q3 2025.
• Investment loss of $56.3 million in 2025, including a significant realized loss of $103.3 million on one transaction.
• Increased tenant concessions/free rent, averaging 1.5 months per annum in 2025, up from 0.7 months in 2024, and projected to increase to 2.0 months in 2026.
• Expected downtime of 6 to 24 months for 1.2 million RSF of key lease expirations in 2026, primarily in Greater Boston, San Francisco Bay Area, and San Diego.
• Projected increase in interest expense to $255 million in 2026 from $227 million in 2025, partly due to decreased capitalized interest from re-evaluating projects.
• Non-income-producing assets represent 17% of gross assets, indicating a substantial portion of capital tied up in non-revenue-generating projects.
• The life science sector is experiencing a prolonged biotech bear market, with venture capital fundraising declining to its lowest level since 2016, impacting demand for lab space.
• Regulatory and policy factors, including FDA leadership turnover, NIH funding uncertainty, and drug pricing scrutiny, are increasing uncertainty for tenants and affecting leasing demand.
• Increased global competition, particularly from China's rapidly expanding biotechnology sector, and U.S. immigration restrictions on international research talent, threaten the long-term viability of the U.S. biomedical industry and demand for life science real estate.
• The net debt and preferred stock to Adjusted EBITDA ratio is expected to temporarily increase by 1.0x to 1.5x in Q1 2026 due to Q4 2025 dispositions and 2026 lease expirations.

Risks

• Inability to identify and complete acquisitions, investments, or development/redevelopment projects successfully and profitably.
• Default on ground leases or inability to renew/re-lease land or space on favorable terms, or tenant inability to pay rent.
• Higher than anticipated costs for maintaining and improving properties, and inability to pass increased operating costs to tenants.
• Liability for environmental damages from tenant use of hazardous materials, or from mold, poor air quality, or other property defects, or increased costs in complying with environmental laws.
• Loss of services of senior officers or key employees and increased competition for skilled personnel, leading to higher labor costs.
• Reliance on a limited number of vendors for utilities and other services, with potential disruption adversely affecting operations.
• Inadequate insurance coverage for potential losses, or costs due to financial condition of insurance carriers.
• Changes in business policies without stockholder approval.
• Failure to maintain effective internal control over financial reporting.
• Failure to qualify as a REIT, leading to corporate taxation and loss of certain deductions.
• Inability to raise sufficient capital due to adverse credit rating changes, inability to refinance existing debt or issue new debt, or inability to sell assets timely or at optimal prices.
• Investment or spending of net proceeds from equity/debt offerings in ways that may not earn a profit.
• Debt service obligations restricting business activities or causing other adverse effects.
• Risks and liabilities associated with investments in partnerships, LLCs, and joint ventures, including partner bankruptcy or inconsistent goals.
• Limits on ownership of stock, potentially leading to loss of beneficial ownership or delaying/preventing desirable transactions.
• Possible future sales of common stock adversely affecting its market price.
• Dependence on the health of the life science industry, with changes, increased competition, or funding issues impacting tenants' ability to pay rent or investment value.
• Market disruption and volatility, poor economic conditions, and tight labor markets adversely affecting equity investments or tenant/investee operations and capital access.
• Actions, policy, or key leadership changes in government agencies, or changes to laws/regulations (tax, accounting, debt, derivatives, government spending, FDA, NIH, tariffs, drug/healthcare pricing) negatively impacting the economy, tenants, and business.
• Partial or complete government shutdown adversely affecting tenants (including government agencies), leading to delays in product commercialization, decreased R&D funding, or budget approval delays.
• Outbreak of highly infectious or contagious disease adversely impacting financial condition and results of operations for the company, tenants, and non-real estate investments.
• Social, political, and economic instability, unrest, significant changes, and other circumstances beyond control (e.g., U.S. political landscape changes) adversely affecting business operations.
• Seasonal weather conditions, climate change, severe weather, and changes in transportation/labor availability affecting business, tenant products/services, or availability.
• Inability to meet sustainability goals.
• Changes in privacy and information security laws/regulations, or non-compliance, leading to fines, penalties, increased costs, or liability.
• System failures or security incidents (cyberattacks, intrusions) disrupting IT networks, applications, causing data loss, remediation expenses, liability, litigation, reputational damage.
• Enactment of legislation, including the Inflation Reduction Act of 2022 (IRA), adversely impacting financial condition and results of operations.
• Increased risks and costs associated with volatility in commodity and labor prices or supply chain/procurement disruptions affecting construction projects.
• Failure to identify and develop relationships with a sufficient number of qualified suppliers and contractors affecting construction quality and status.
• Increased risks and costs for tenants associated with volatility in commodity and labor prices or specialized materials/equipment, or supply chain disruptions.
• Difficulty in predicting revenue potential from new property acquisitions or developments.
• Failure to achieve expected financial results from development or redevelopment projects.
• Increased operating costs not fully recoverable from tenants.
• Inability to renew leases or re-lease space on favorable terms as leases expire.
• Properties having defects unknown to the company.
• Inability to obtain additional capital to further business objectives.
• Inability to sell properties quickly to raise capital due to illiquid nature of real estate assets or tax implications.
• Unsecured senior line of credit restricting certain business activities.
• Market price and volatility of common stock adversely affected by financial performance, market expectations, and external factors.
• Distributions to stockholders declining at any time.
• Ownership interests outside the U.S. subjecting the company to different or greater risks (e.g., exchange rates, repatriation, foreign regulations).
• Market and other external factors adversely impacting the valuation and liquidity of non-real estate equity investments.
• Negative impact on economic growth from federal income tax policy, debt policy, and government spending.
• Changes to U.S. tax laws and implementation of new tax policies negatively impacting the economy, tenants, and business (e.g., OBBB Act).
• Actual and anticipated changes to healthcare system regulations negatively impacting drug pricing, healthcare costs, and reimbursement.
• U.S. government tenants not receiving anticipated appropriations, hindering their ability to pay rent.
• Increasing government price controls and other healthcare cost-containment measures affecting tenants' revenue and profitability.
• Changes to U.S. government funding, staffing, trade, policies, and other federal actions adversely affecting business operations or those of tenants/venture investments (e.g., FDA/NIH workforce reductions, grant cuts, drug pricing regulation, China's biotech expansion, tariffs).
• Increased use of AI and automation in life science R&D changing space configurations and tenant requirements in unforeseen ways.
• Short sellers engaging in manipulative activity intended to drive down stock price, diverting management time and leading to inquiries.
• Cash and cash equivalents held in deposit accounts exceeding FDIC insurance coverage, posing credit risk if financial institutions fail.

Future Outlook

The company anticipates continued challenges in the life science real estate market due to oversupply and reduced demand, leading to further declines in operating occupancy and rental rates in 2026. It projects FFO per share (as adjusted) to be between $6.25 and $6.55 for 2026. The company plans to mitigate these headwinds through disciplined capital allocation, strategic asset recycling, and cost control, aiming for a net debt and preferred stock to Adjusted EBITDA ratio of 5.6x to 6.2x by Q4 2026. The outlook is cautious, with a focus on maintaining balance sheet strength and leveraging its Megacampus strategy.

Management Comments

• Our Megacampus ecosystems represent the most competitive segment of the life science real estate market, offering superior amenities, services, and access to transit, which are critical for attracting and retaining top talent.
• Our Megacampus strategy represents our most powerful competitive advantage in an oversupplied market, enabling us to capture an outsized share of leasing demand.
• The decision to reduce the declared dividend per common share reflects our commitment to maintaining the strength of our balance sheet, enhancing financial flexibility, and preserving liquidity of approximately $410 million on an annual basis, which will be used to support our 2026 capital plan.
• We believe the mitigating factors discussed will help us manage prolonged market volatility while maintaining the flexibility to act on strategic opportunities.
• Through disciplined execution of non-core asset recycling, targeted capital allocation, continued focus on our Megacampus platform, moderated construction spending, and preservation of balance sheet strength, we are building a resilient platform designed to deliver sustainable growth and value creation across multiple cycles.
• We believe these actions position us to emerge from the current cycle in a position of strength.

Industry Context

The life science real estate industry is facing significant headwinds, including a surge in new supply from repurposed office spaces and a substantial decrease in tenant demand, which has moderated to pre-pandemic levels. The biotech sector is in its fifth consecutive year of a bear market, with venture capital fundraising at its lowest since 2016 and a highly risk-averse investment environment. Regulatory and policy changes, such as FDA leadership turnover, NIH funding uncertainty, and drug pricing scrutiny, are exacerbating market uncertainty. Increased global competition, particularly from China's rapidly expanding biotechnology sector, and U.S. immigration restrictions on international research talent, pose long-term threats to the U.S. biomedical industry's global leadership and demand for domestic lab space. The company's focus on 'Megacampus' ecosystems and high-quality tenants is a strategy to differentiate itself in this challenging environment, while the broader market sees elevated vacancy rates, slower leasing, and increased concessions.

Comparison to Industry Standards

• The company's 2025 general and administrative expenses as a percentage of net operating income (5.6%) are approximately half the average of other S&P 500 REITs, indicating superior cost efficiency.
• The weighted-average remaining term of the company's debt (12.1 years) is the longest among S&P 500 REITs, suggesting a more stable and long-term debt structure compared to peers.
• The company's voluntary and total turnover rates (4.6% and 9.3% respectively from 2021-2025) are below the REIT industry averages (12.0% and 17.0% respectively as reported in the 2025 Nareit Compensation & Benefits Survey), indicating strong employee retention.
• The company's credit ratings (BBB+ from S&P Global Ratings and Baa1 from Moody's Ratings) rank in the top 15% among all publicly traded U.S. REITs, reflecting a strong credit profile relative to the industry.

Management Changes

Corporate Governance

Legal Proceedings

• ARE-East River Science Park, LLC filed a lawsuit on August 6, 2024, against New York City Health + Hospitals Corporation (H+H) and New York City Economic Development Corporation (EDC) in the U.S. District Court for the Southern District of New York.
• The lawsuit alleges fraud in the inducement and breach of contract, claiming H+H and EDC misrepresented and concealed material facts regarding a floodwall required for the development of an Option Parcel adjacent to the Alexandria Center for Life Science – New York City campus.
• The company has invested $178.1 million in pre-construction costs for the Option Parcel as of December 31, 2025.
• The litigation has made the closing date for the option and the commencement date for construction of the third tower indeterminate.
• ARE-East River Science Park, LLC is seeking significant damages and equitable relief to confirm the option is in full force and effect.
• A probability-weighted recoverability analysis determined no impairment was present as of December 31, 2025, regarding the $178.1 million investment, but potential losses range from zero to the full investment amount.

Related Party Transactions

• In September 2025, the company completed an exchange of partial interests in two consolidated joint ventures, Pacific Technology Park and 199 East Blaine Street, with one joint venture partner, resulting in a sales price received by cash of $1.6 million.
• In December 2025, the consolidated joint venture owning properties at 409 and 499 Illinois Street sold these properties to an existing tenant following its exercise of a purchase right included in its lease agreement. The company had a 25.0% ownership interest in this joint venture.
• In December 2025, the company sold its 60.0% ownership interest in a consolidated joint venture at 285, 299, 307, and 345 Dorchester Avenue to its partner for $33.5 million.
• In January 2026, the partner in the consolidated joint venture at 99 Coolidge Avenue exercised its option to require the company to purchase its redeemable noncontrolling interest aggregating $48.7 million plus unpaid distributions.

Stakeholder Impact

• **Shareholders:** Negative impact due to significant net loss, reduced FFO per share, a 45% dividend cut, and substantial real estate impairments. Future share price volatility is expected. Potential for dilution if equity offerings are used for capital raises. The new share repurchase program could provide some support.
• **Employees:** Positive impact from below-industry-average turnover rates (4.6% voluntary, 9.3% total) and robust benefits package covering 100% of insurance premiums for employees and dependents. Professional development and mentoring programs are offered. However, headcount reductions and compensation plan restructuring were part of cost-control initiatives.
• **Tenants:** Mixed impact. High-quality Megacampus ecosystems are designed to attract and retain talent, with 82% of 2025 leasing from existing tenants. However, tenants face increased occupancy costs due to triple net leases and potential impacts from regulatory changes (FDA, NIH, drug pricing) and macroeconomic conditions, which could affect their ability to pay rent or renew leases. Some tenants may experience delays due to government shutdowns or supply chain disruptions.
• **Creditors:** The company maintains strong credit ratings (BBB+, Baa1) and a well-laddered debt maturity schedule, with 97.2% fixed-rate debt, providing predictability. However, the temporary increase in net debt and preferred stock to Adjusted EBITDA ratio in Q1 2026 and potential for higher borrowing costs due to elevated interest rates could be a concern.
• **Suppliers/Contractors:** Potential for increased costs and delays due to volatility in commodity and labor prices, and supply chain disruptions. The company relies on a limited number of vendors for key services, creating risk if these vendors face difficulties.

Next Steps

• Complete $2.90 billion in dispositions and sales of partial interests in 2026 to fund development projects and reduce debt.
• Continue to evaluate business strategies for 1.2 million RSF of projects under construction, including continuing construction, selling, or pausing development/redevelopment.
• Repay $300.0 million of 4.30% unsecured senior notes payable in January 2026 (already completed).
• Repay existing short-term borrowings, including commercial paper program, and potentially other unsecured senior notes payable (e.g., 2027 maturity).
• Redeem a $48.7 million noncontrolling interest in the 99 Coolidge Avenue joint venture in Q1 2026 (partner exercised option).
• Monitor and manage the re-leasing of 1.2 million RSF of key lease expirations in 2026, with expected downtime of 6-24 months.
• Continue to implement cost-control and efficiency initiatives to manage general and administrative expenses.
• Finalize 2025 REIT taxable income when filing the 2025 federal income tax return in 2026.
• Continue to refine climate resilience roadmap and GHG emissions mitigation strategy, including implementing resilient design guidelines for new properties and landscaping improvements for wildfire-prone areas.
• Monitor the outcome of the lawsuit against New York City Health + Hospitals Corporation and New York City Economic Development Corporation regarding the Option Parcel development.

Key Dates

Recommendation

The company reported a substantial net loss of $1.44 billion for 2025, a significant deterioration from the prior year's profit, primarily driven by $2.20 billion in real estate impairment charges. This indicates a material decline in asset values and a challenging market for its properties. The 45% dividend cut signals a need to conserve capital and reflects a weaker financial position. Furthermore, the projected decline in operating occupancy to 88.5% and negative cash rental rate changes for renewed/re-leased space in 2026 suggest ongoing operational headwinds. While the company is taking steps to mitigate risks through capital recycling and cost control, the immediate outlook is negative, with significant market volatility, reduced demand in the life science sector, and regulatory uncertainties. These factors collectively point to continued pressure on earnings and potential further erosion of shareholder value, making a 'sell' recommendation appropriate for a seasoned investor.

Keywords

Life Science Real Estate, REIT, Alexandria Real Estate Equities, ARE, Megacampus, Biotechnology, Pharmaceutical, Lab Space, SEC Filing, 10-K, Financial Performance, Real Estate Impairment, Dividend Cut, Capital Recycling, Occupancy Rates, Leasing Activity, Venture Capital, Risk Factors, Corporate Governance, Maryland Corporation, NYSE, ARE, S&P 500, AAA Locations, Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, New York City, Texas, Triple Net Leases, Debt Management, Credit Ratings, Environmental Risks, Cybersecurity, Inflation Reduction Act, FDA, NIH, Agtech, Technology Industry, Executive Compensation, Share Repurchase Program, Joint Ventures, Cash Flow, Operating Income, Capital Expenditures, Market Volatility